Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months. We make a negative revision reflecting the slow launch progress and a more stretched funding outlook. Our Base Case is SEK100 (175) with a Bull Case of SEK200 (400) and a Bear Case of SEK15 (45).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Hansa Biopharma Q3 update - Slow progress ahead of 2024

© Modular Finance, source Nordic Press Releases